## Table 2 |
|||

Comparison of baseline characteristics of Nigerian adults lost-to-follow-up and participating in the HACART study at 12 months |
|||

Characteristics |
Lost-To-Follow-Up |
Study participants |
p-value^{§} |

(n = 805) |
(n = 628) |
||

Gender |
0.99 | ||

Female | 513 (63.7%) | 400 (63.7%) | |

Male | 292 (36.3%) | 228 (36.3%) | |

Age at HAART Initiation (years) |
0.04 | ||

Median (Inter-quartile range) | 33 (28–40) | 35 (30–41) | |

< 30 | 304 (37.7%) | 190 (30.3%) | |

31 to 40 | 306 (38%) | 271 (43.1%) | |

41 to 50 | 139 (17.3%) | 120 (19.1%) | |

>50 | 56 (7%) | 47 (7.5%) | |

Marital Status (n = 2398)^{‡} |
0.15 | ||

Single | 184 (24.7%) | 146 (23.2%) | |

Married / Cohabiting | 449 (60.4%) | 359 (57.2%) | |

Separated | 40 (5.4%) | 45 (7.2%) | |

Divorced / Widowed | 71 (9.5%) | 78 (12.4%) | |

Currently married (n = 2398) |
0.23 | ||

Yes | 449 (60.3%) | 359 (57.2%) | |

No | 295 (39.7%) | 269 (42.8%) | |

Residential Distance (in kilometers) (n = 2295) ^{‡} |
0.001 | ||

Median (inter-quartile range) | 15 (10–75) | 25 (10–80) | |

< 50 | 486 (60.4%) | 402 (64%) | |

51 and < 100 | 134 (16.7%) | 80 (12.7%) | |

101 and <200 | 100 (12.4%) | 120 (19.1%) | |

>=200 | 13 (1.8%) | 26 (4.1%) | |

HIV disclosure (n = 2082) ^{‡} |
0.28 | ||

Yes | 481 (93.2%) | 595 (94.7%) | |

No | 35 (6.8%) | 33 (5.3%) | |

Tuberculosis History (n = 2025) ^{‡} |
0.76 | ||

Yes | 72 (13.7%) | 90 (14.3%) | |

No | 453 (86.3%) | 538 (85.7%) | |

Baseline CD4 count (n = 2033) ^{‡} |
0.001 | ||

Median (inter-quartile range) | 119 (54–218) | 142 (85–223) | |

< 50 | 137 (22.6%) | 88 (14.4%) | |

>=50 and < 200 | 301 (49.7%) | 336 (54.8%) | |

>=200 and <350 | 99 (16.3%) | 155 (25.3%) | |

>=350 and < 500 | 29 (4.8%) | 24 (3.9%) | |

>=500 | 40 (6.6%) | 10 (1.6%) | |

Baseline Hemoglobin (g/dl) (n − 1606) ^{‡} |
0.001 | ||

Median (inter-quartile range) | 9.9 (8–11.5) | 10.9 (9.3-12.4) | |

> =10 | 228 (48.6%) | 354 (64.8%) | |

>=8 and <10 (Grade 1 anemia) | 127 (27.1%) | 141 (25.8%) | |

>=7 and <8 (Grade 2 anemia) | 42 (9%) | 33 (6%) | |

>=6.5 and <7 (Grade 3 anemia) | 14 (3%) | 7 (1.3%) | |

< 6.5 (Grade 4 anemia) | 58 (12.4%) | 11 (2%) | |

Baseline anemia (Hemoglobin < 10g/dl) |
0.001 | ||

Yes | 241 (51.4%) | 192 (35.2%) | |

No | 228 (48.6%) | 354 (64.8%) | |

Antiretroviral drug regimen at baseline |
0.001 | ||

ZDV / 3TC / NVP or EFV | 276 (34.3%) | 275 (40.9%) | |

D4T / 3TC / NVP or EFV | 193 (24%) | 50 (8%) | |

TDF / 3TC of FTC / NVP or EFV | 336 (41.7%) | 321 (51.1%) |

*Categorical variables expressed as n *(%) *and continuous variables almost expressed as median *(*inter*-*quartile range*)

^{§ }p-values comparing study participant variables across the three study sites calculated
from Kruskal-Wallis test statistic for continuous variables and Pearson χ^{2 }test statistic for categorical variables.

Anude * et al.*

Anude * et al.* *BMC Infectious Diseases* 2013 **13**:113 doi:10.1186/1471-2334-13-113